Boston, Massachusetts 02215


Purpose:

The objective of this trial is to assess if Fecal Microbiota Therapy (FMT) can reduce the risk of endoscopic recurrence of CD in patients after intestinal resection. The specific outcomes of FMT to be examined are: 1) endoscopic appearance, 2) clinical symptoms, 3) safety and tolerability, and 4) microbial diversity. The research team hypothesizes that FMT will prevent establishment of "pro-inflammatory" microbiome after surgery, leading to a reduced probability of recurrence of macroscopic inflammation. It is also hypothesized that FMT will be safe and well-tolerated in these patients.


Criteria:

Inclusion Criteria (Patients): - Adults (age > 18) - Confirmed diagnosis of Crohn's disease, based on endoscopy, histology and imaging (confirmed by Study PI for each site) - Ileo-cecal resection or terminal ileal resection for CD within 30 days prior to enrollment - Resection margins & anastomosis free of active inflammation based on histology and surgical description (confirmed by Study PI for each site) - No therapy to prevent post-operative recurrence of CD. A 30-day wash-out period for anti-TNFs, thiopurines, antibiotics will be required prior to enrollment. Exclusion Criteria (Patients): - Diagnosis of indeterminate colitis - Women who are pregnant or nursing - Patients who are unable to give informed consent - Patients who are unable or unwilling to undergo colonoscopy with moderate sedation (>ASA class II) - Patients who have previously undergone FMT - Patients who have a confirmed malignancy or cancer - Participation in a clinical trial in the preceding 30 days or simultaneously during this trial - Probiotic use within 30 days of start date - Decompensated cirrhosis - Congenital or acquired immunodeficiencies - Chronic kidney disease as defined by a GFR <60mL/min/1.73m2 44 - History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia from colonoscopy


NCT ID:

NCT02417974


Primary Contact:

Principal Investigator
Alan C Moss, MD
Beth Israel Deaconess Medical Center

Amanda Ting
Phone: 617-667-0558
Email: ajting@caregroup.org


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02215
United States

Amanda Ting
Phone: 617-667-0558
Email: ajting@caregroup.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.